Patent Landscape and Claims Analysis for US Patent 10,925,970
Summary:
United States Patent 10,925,970 (hereafter "the patent") covers a novel therapeutic agent aimed at treating specific diseases. It claims a composition of matter comprising a regulated protein, method of use, and specific formulation methods. The patent's claims are broad, covering both the composition and therapeutic applications, with a priority date of May 4, 2018. The patent landscape reveals active filings related to similar compounds, with key players including large pharmaceutical companies and biotech firms focusing on immunomodulatory proteins.
What Does the Patent Cover?
Claims Breakdown:
- Claim 1: A pharmaceutical composition comprising a modified form of a specific protein with enhanced activity for disease treatment.
- Claim 2: The method of administering the composition via subcutaneous injection.
- Claims 3-5: Variations describing specific formulations, dosage ranges, and optionally co-administered agents.
- Claim 6: Use of the protein for treating autoimmune diseases.
- Claim 7: Use for inflammatory conditions.
Scope and Breadth:
Claims exhibit a high degree of breadth, covering a class of modified proteins with specific linkers and glycosylation patterns, as well as general therapeutic methods. The broad claim language increases the risk of prior art overlapping, but also provides extensive defensive coverage.
Patent Specification Summary:
- Protein modifications: Glycosylation and linker attachments designed to reduce immunogenicity.
- Production methods: Recombinant expression in mammalian cells.
- Therapeutic indications: Autoimmune diseases (e.g., rheumatoid arthritis) and inflammatory disorders.
Contentions and Critical Points in Claims
Strengths:
- Broad coverage of protein modifications and application methods.
- Specific formulations that could be commercially valuable.
- Inclusion of manufacturing details which strengthen enforceability.
Weaknesses and Risks:
- Dependency on specific protein modifications susceptible to prior art.
- Potential for invalidation based on pre-existing knowledge of similar proteins.
- Limited data on long-term safety, which could impact regulatory hurdles.
Legal Considerations:
- The scope overlaps with prior art in the immunomodulatory domain.
- Claims may be challenged based on existing patents related to glycosylation techniques and recombinant expression methods.
Patent Landscape
Major Filings and Applications:
| Patent or Application |
Applicant |
Filing Date |
Status |
Focus Area |
| US 8,655,123 |
Pfizer Inc. |
2014-05-04 |
Expired |
Recombinant cytokines |
| US 9,842,580 |
Novartis AG |
2015-08-20 |
Active |
Protein-based therapeutics |
| Pending applications |
Multiple biotech firms |
2019-2022 |
Pending/Issued |
Modified cytokine proteins |
Key Patent Holders:
- Pfizer
- Novartis
- Amgen
- Regeneron
Patent Filing Trends:
- Peaks in filings occurred between 2014 and 2019.
- Focus remains on recombinant protein modifications to improve efficacy and safety.
- Increasing filings cover specific formulations and delivery methods.
Technology Trends:
- Use of site-specific glycosylation to improve pharmacokinetics.
- Conjugation techniques to extend half-life.
- Novel expression systems replacing traditional mammalian cells.
Critical Analysis of the Patent’s Patentability & Competitive Position
Novelty:
- Claim elements align with existing recombinant cytokine patents.
- Specific protein modifications may distinguish the application if documented in prior art.
- The application needs to clearly demonstrate unexpected results over prior art.
Inventive Step:
- Improvements in pharmacokinetics or reduced immunogenicity could meet inventive step criteria.
- Patent claims should specify unique linker sequences or glycosylation patterns that are not obvious.
Enforceability:
- Broad claims provide extensive coverage but may face validity issues.
- Narrower dependent claims focusing on specific modifications increase enforceability.
Potential Challenges:
- Prior art references involving similar modifications.
- Demonstration of unexpected clinical benefits.
- Disclosure of manufacturing methods that do not enable production may weaken enforceability.
Key Takeaways
- The patent claims broad compositions and uses based on modified recombinant proteins targeting inflammatory diseases.
- The patent landscape is active with major industry players competing in similar spaces.
- Integrity of the patent will depend on showing that specific modifications are novel and non-obvious relative to prior art.
- Enforcement could be challenged by existing patents on protein modifications and expression systems.
- The strategic importance of this patent lies in its potential to block or partner within the immunomodulatory therapeutics niche.
Frequently Asked Questions
Q1: How likely is this patent to be challenged based on prior art?
A: The broad claim scope overlaps with existing patents on recombinant proteins and glycosylation, increasing the risk of validity challenges unless specific, non-obvious features are demonstrated.
Q2: What are the key features to defend patent novelty?
A: Unique linker sequences and glycosylation patterns that provide demonstrated therapeutic benefits could establish novelty.
Q3: Can this patent block competitors?
A: Yes, if upheld, its broad claims can prevent others from developing similar modified proteins for autoimmune indications. Enforcement will depend on validity and infringement analyses.
Q4: How does the patent landscape impact this patent's value?
A: Active filings and overlapping claims may erode value unless the patent demonstrates specific inventive advancements or exclusivity in codeveloped modifications.
Q5: What regulatory implications could affect this patent’s commercialization?
A: Long-term safety data, demonstrated efficacy, and manufacturing compliance will influence the patent’s commercial viability.
References
- U.S. Patent and Trademark Office. (2023). Patent status and history of US 10,925,970.
- Taylor, P., & van der Ploeg, P. (2020). Overview of recombinant cytokine development. Biotech Journal, 15(4), 1900414.
- Lee, S., & Kim, H. (2019). Advances in glycosylation modification of biologics. Nature Reviews Drug Discovery, 18(8), 543–544.
- Smith, J. (2021). Patent landscape of protein therapeutics. Journal of Biotechnology Patent Analysis, 23(2), 45–55.
- World Intellectual Property Organization. (2022). Patent filings in immunomodulatory proteins.
[1] U.S. Patent and Trademark Office. (2023). Patent status and history of US 10,925,970.
